Psychedelics Stocks

Aion Therapeutic
(CSE:AION)

Aion Therapeutic is an international pharmaceutical company that uses Artificial Intelligence (AI) to create disease-specific cannabis and psilocybin formulations. The company filed four new patents in March 2021 focusing on the use of medicinal mushrooms for cancer patients.

Share this Psychedelco content with friends!

Algernon Pharmaceuticals
(CSE:AGN,OTCQB:AGNPF)

Algernon Pharmaceuticals is a clinical stage company that looks for ways to re-purpose existing pharmaceuticals for new disease applications. They are currently researching DMT’s non-psychedelic potential for the recovery of brain tissue in stroke survivors.

ATAI Life Sciences
(NASDAQ:ATAI)

ATAI Life Sciences develops novel therapeutic drugs, including psychedelics, to help treat mental health conditions like depression, anxiety, traumatic brain injury, and PTSD. They are in the clinical stage of development, having raised considerable capital through their initial NASDAQ public offering, including $12 million from PayPal Co-Founder, Peter Thiel.

Awakn Life Sciences
(NEO:AWKN,OTC Pink:AWKNF)

Awakn Life Sciences is a biotech company that focuses on the research, development, and delivery of psychedelic therapeutics. They hope to use psychedelic medicines to treat depression, anxiety, PTSD, and depression. They’ve recently raised more than $225 million in funding through their initial NASDAQ public offering. As such, Awakn Life Sciences is one of the best publicly traded psychedelic companies to watch.

Better Plant Sciences
(CSE:PLNT,OTCQB:VEGGF)

Better Plant Sciences is a vertically integrated company that focuses on plant-based wellness products. Their parent company, NeonMind Biosciences (formerly called Flourish Mushroom Labs) has confirmed that the biotech company will begin psilocybin clinical trials with plans to sell branded mushroom-based products to help support cognition, memory, immune system functioning.

BetterLife Pharma
(CSE:BETR,OTCQB:BETRF)

BetterLife Pharma is a second-generation psychedelics company that develops commercial psychedelic products for distribution in the USA, Canada, Australia, and the European Union. They hope to use an LSD derivative to help treat severe forms of treatment-resistant depression. Notably, BetterLife Pharma is currently testing LSD in the pre-clinical stage for substance abuse treatment and plans to begin the next round of trials in 2022. They are also researching potential COVID-19 treatments.

Braxia Scientific
(CSE:BRAX,OTC Pink:SHRMF)

Braxia Scientific develops psychedelic derivatives and operates multidisciplinary community-based clinics to help treat mental health disorders quickly and efficiently. They currently have clinics in Toronto, Mississauga, Ottawa, and Montreal. The recently launched Braxia Institute is now researching ketamine- and psychedelic-based therapy for patients suffering from treatment-resistant depression.

Bright Minds Biosciences
(CSE:DRUG,OTCQB:BMBIF)

Bright Minds Biosciences researches serotonin system functioning to determine precise corelations between specific serotonin agonists and related mental health problems. They then use this information to develop superior first-generation compounds out of substances like psilocybin. The company recently applied for NASDAQ listing.

Captiva Verde Wellness
(CSE:PWR)

Captiva Verde Wellness is a cannabis company that recently joined the psychedelic space when after partnering with Mexican pharmaceutical company, Esmeralda. The global health and wellness company is now poised to distribute both psychedelic and non-psychedelic products directly to consumers, including large-scale quantities of micro-dosed mushroom products.

Clearmind Medicine
(CSE:CMND)

Clearmind Medicine develops psychedelic medicines to help treat mental health conditions like binge eating and alcohol abuse. One of their patents, an alcohol substitute, is approved in Europe and pending approval in the US, India, and China. Their second patent for binge behavior has already been approved in those same four locations.

Codebase Ventures
(CSE:CODE,OTCQB:BKLLF)

Investment company, Codebase Ventures, helps investors diversify their portfolios by offering direst stakes companies like psychedelic company, Red Light Holland. They also focus on things like cryptocurrency and cannabis/CBD companies.

COMPASS Pathways
(NASDAQ:CMPS)

COMPASS Pathways is one of the most popular publicly traded psychedelic companies on the market. The psychedelic research company gained breakthrough therapy research approval through the FDA in 2018. Its first research program seeks to develop psilocybin therapy for those suffering from treatment-resistant depression. Late-stage clinical trials are currently happening in Europe and North America.

Core One Labs
(CSE:COOL, OTC Pink:CLABD)

Core One Labs is a biotech company that develops front-facing psychedelic medicines like thin-film oral strips. They also provide psychedelic-assisted psychotherapy to help treat mental health problems and addiction

Creso Pharma
(ASX:CPH,OTCQB:COPHF)

Creso Pharma is a cannabis/hemp company specializing in enhanced cannabinoid bioavailability and absorption. They develop lifestyle products like their patent-pending water-soluble cannabinoid powder, and have recently joined the psychedelic space by acquiring Halucenex Life Sciences. They also plan to merge with Red Light Holland to build the HighBrid Lab.

CURE Pharmaceutical Holding
(OTCQB:CURR)

CURE Pharmaceutical Holding develops immediate- and controlled-release drug-delivery technology to help improve drug safety, efficacy, and patient experiences. They’ve recently added psychedelic-based drugs to their pipeline and created an oral film delivery system to accommodate those who have limited access to safe drinking water or have difficulty swallowing pills.

Cybin Corp.
(NYSEAMERICAN:CYBN,NEO:CYBN)

Cybin is a life science company dedicated to improving mental health through psychedelic therapy. Importantly, they employ technology-enhanced screening processes to ensure optimal medications and drug delivery systems to support long-term recovery. As such, they aim to address the underlying causes of mental health problems rather than treat the symptoms.

EGF Theramed Health
(CSE:TMED,OTC Pink:EVAHF)

EGF Theramed Health frames itself as a pioneer in the psychedelic space by exploring and improving psychedelic delivery methods to help treat things like alcohol addiction, anxiety, PTSD, and depression. The FDA recently granted the company breakthrough status for its psychedelic research, suggesting that the compounds “preliminary clinical evidence indicate that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.”

Ehave
(OTC Pink:EHVVF)

Ehave is a publicly traded psychedelic company that studies the cause of HPPD, or Hallucinogen-persisting perception disorder. Researchers believe that those who experience these persistent sensory disturbances resulting from past hallucinogenic drug experiences may have a genetic predisposition to the problem. As such, the company will conduct large-scale genetic analyses to determine who is at risk for the disorder.

Empower Clinics
(CSE:CBDT,OTC Pink:EPWCF)

Empower Clinics is a health and wellness brand that operates a multi-state network of clinics that focus on innovative mental health treatment options. With more than 165,000 patients in its care, the team seeks to improve mental health at scale using alternative treatment options like hemp-derived CBD and psilocybin therapy.

Entheon Biomedical
(CSE:ENBI,OTCQB:ENTBF)

Entheon Biomedical is a biotech company working to develop psychedelic (ketamine) treatment options to aid in addiction recovery. Additionally, they hope to pinpoint the cause of substance abuse disorder using DMT to significantly reduce the occurrence of “untreatable” addiction.

Enveric Biosciences
(NASDAQ:ENVB)

Enveric Biosciences is a primarily cannabinoid-focused company. However, they recently acquired MagicMed Industries, thus launching them into the psychedelic space. The acquisition expands Enveric’s portfolio to include psychedelic compounds like psilocybin and DMT.

Field Trip Health
(TSX:FTRP,NASDAQ:FTRP)

Field Trip Health is a clinical network throughout North America that delivers psychedelic-assisted therapy. Usually, treatment occurs through a series of sessions during which therapists prepare the patient, engage in psychedelic therapy, then integrate the experience. Their first ketamine clinic opened in Toronto, though they now have clinics in New York, Los Angeles, Chicago, Atlanta, Houston, and Amsterdam. Notably, former Pfizer Executive, Michael Ehlers, is Field Trip’s newly-appointed Strategic Advisor.

Field Trip Health, Inc.
(OTCQX: FTRPF)

Field Trip Health is a Canadian health company that operates clinics focused on psychedelic therapy and plant-based psychedelic research. The company hopes to open five clinics in its first year and have 75 clinics established by the end of 2023. There are currently three open Field Trip Health clinics that conduct ketamine-enhanced therapeutic sessions. Those clinics are located in Toronto, New York, and Los Angeles.

Filament Health
(NEO:FH)

Filament Health is a psychedelic drug company that focuses on drug discovery and compound extraction technology to address a global mental health crisis. Importantly, they are currently conducting two FDA-approved clinical trials to test the efficacy of natural psychedelic compounds, including DMT, mescaline, harmaline, and more.

GH Research
(NASDAQ:GHRS)

GH Research develops novel DMT therapy for those who suffer from treatment-resistant depression. This publicly traded psychedelic company has completed Phase 1 clinical trials in healthy volunteers, which seems to suggest significant improvement after a single dose of psychedelics. They are currently conducting Phase 2 of their ongoing clinical trial to determine if a second higher dose produces a more substantial benefit.

Global Trac Solutions
(OTC Pink:PSYC)

Global Trac Solutions is a publicly traded digital media company that focuses on emerging psychedelic medicine. The newly-launched platform features news and information about the psychedelic industry.

Goodness Growth Holdings
(CSE:GDNS,OTCQX:GDNSF)

Though primarily a multi-state cannabis company, Goodness Growth Holdings recently entered the psychedelic space when it filed a US patent for virtual reality technology for use during psychedelic therapy. Importantly, the scalable platform allows clinicians to customize virtual environments to help optimize the therapeutic experience.

Graph Blockchain
(CSE:GBLC)

Graph Blockchain recently acquired Shroom Street for $1M. The company plans to integrate blockchain technology with product-tracking tools in the psychedelic industry.

Havn Life Sciences
(CSE:HAVN,OTC Pink:HAVLF)

Havn Life Sciences researches and develops psilocybin medicines following Health Canada’s Section 56 exemption. This publicly traded psychedelic company researches, extracts, formulates, and delivers psychedelic medicines as an innovative approach to mental health. Notably, company advisors include many popular Canadian cannabis players, including Vic Neufeld of Aphria.

Hollister Biosciences
(CSE:HOLL,OTC Pink:HSTRF)

Hollister Biosciences is a cannabis company that recently joined the psychedelic space when it acquired AlphaMind Brands for $1.2M. The company hopes to build a portfolio of legal mushroom-based health products in addition to its extensive cannabis listings.

KetamineOne Capital
(NEO:MEDI,OTC Pink:KONEF)

KetamineOne Capital operates plant-based healthcare clinics throughout North America to help treat mental health and emotional pain. Importantly, their ketamine-enhanced treatments help provide life-changing mental health services through wearable technologies that track key vitals before, during, and after psychedelic therapy. The company has been studying psychedelic therapies for over 23 years. Consequently, the company is well-equipped with cutting-edge technologies, research techniques, and seasoned industry experts.

Levitee Labs
(CSE:LVT,OTC Pink:LVTTF)

Levitee Labs is a multidisciplinary wellness company that seeks to prevent, restore, and improve mental health conditions through novel psychedelic therapies. Their innovative, evidence-based model uses psychedelic medicines to reduce inefficiencies within our current mental healthcare system, including improved access to mental health support for underserved populations.

Lobe Sciences
(CSE:LOBE,OTC Pink:GTSIF)

Lobe Sciences includes a team of scientists, engineers, and physicians dedicated to improving brain health with psychedelic medicines. They currently have five patents pending, including medicines and devices that can help treat PTSD and Traumatic Brain Injury. Their current focus is on both Psilocybin and MDMA therapy as well as patent-pending medical devices that deliver these compounds through the nasal cavity.

M2Bio Sciences
(OTC Pink:WUHN)

M2Bio Sciences is a biotech company that develops cannabinoid and psilocybin-based medicines via its wholly-owned subsidiary company, MJ MedTech. Notably, the company issues commercial products under the brand names Liviana, Medspresso, Dr. AnnaRx, and Handcrafted Delights. Their innovative therapies seek to assist those suffering from mental health disorders, Alzheimer’s and Parkinson’s Disease.

Mind Cure Health
(CSE:MCUR,OTCQB:MCURF)

Mind Cure Health combines technology and research to revolutionize the mental wellness journey. They synthesize psychedelic compounds and develop treatment protocols that target specific brain receptors for enhanced mental health. They also offer a compatible software called iSTRYM to help both patients and clinicians navigate the complex mental health journey.

Mind Cure Health Inc.
(OTCQB: MCURF)

Mind Cure Health Inc. is a Canadian biotech company that produces and distributes mushroom powders and supports synthetic psychedelic research. The company boasts its multi-dimensional approach to therapy through psychedelic medicines, clinician support, and mobile technology.

Mind Medicine
(NASDAQ: MNMD)

Mind Medicine is a biotech company backed by many high-profile investors. The company is developing psychedelic therapies, including psilocybin, DMT, MDMA, and LSD, to potentially help treat addiction and mental health issues.

Mind Medicine
(NASDAQ:MNMD,NEO:MMED)

Mind Medicine offers breakthrough psychedelic medicines and technology to help patients achieve sustained mental healing. The company was the first psychedelic company to make its public debut on Toronto’s NEO stock exchange in 2020. Consequently, since then, many well-known investors have taken an interest in the company, including Founder and former Canopy Growth Corp CEO, Bruce Linton and Shark Tank’s Kevin O’Leary. As such, Mind Medicine is one of the most popular publicly traded psychedelic companies on the market today.

Mindset Pharma (CSE:MSET,OTCQB:MSSTF)
(CSE:MSET,OTCQB:MSSTF)

Toronto-based drug company Mindset Pharma creates novel psychedelic compounds to help treat neurological and psychiatric disorders. They hope to build a large library of psychedelic intellectual property to help address neuropsychiatric disorders.

Mydecine Innovations Group
(OTCPK: MYCOF)

Mydecine Innovations Group is a nature-based medicine group designed to help combat mental illness. The company is currently developing an artificial intelligence/machine learning-based drug screening process. Their aim is to more efficiently expand our knowledge of psychedelic substances. Though Mydecine Innovations stock prices are exceptionally low at this time (currently under $0.50 per share), the technology that backs the company will soon explode its market value.

Mydecine Innovations Group (OTC Pink:MYCOF,NEO:MYCO)
(OTC Pink:MYCOF,NEO:MYCO)

NewLeaf Brands acquired Mydecine Group for $1.2M to create the Mydecine Innovations Group in June 2020. Notably, Mydecine Innovations Group is a biotech and life sciences company that develops medical-grade products from both psychedelic and non-psychedelic mushrooms. Health Canada has certified the company to cultivate, extract, distribute, and analyze various mushroom compounds for treating certain mental health conditions, particularly PTSD.

NeonMind Biosciences (CSE:NEON,OTCQB:NMDBF)
(CSE:NEON,OTCQB:NMDBF)

NeonMind Biosciences develops consumer goods to help promote weight loss with psilocybin. The company hopes to deliver a line of functional foods to address obesity, noting the high worldwide prevalence coupled with psilocybin’s tendency to curb appetite. They currently offer an expansive coffee line in Canada and hope to expand distribution to a global market soon.

New Wave Holdings (CSE:SPOR,OTC Pink:TRMNF)
(CSE:SPOR,OTC Pink:TRMNF)

New Wave Holdings is an investment firm that focuses on three different psilocybin markets: recreational, natural (health and beauty), and mental health. They currently have two production facilities in Jamaica and established export agreements with Brazil and the Netherlands.

Novamind
(CSE:NM,OTC Pink:NVMDF)

Novamind operates a wide network of psychedelic clinics, research sites, and therapeutic retreats. Specifically, they specialize in ketamine-assisted therapy as a means of innovative, evidence-based mental health care. Additionally, they hope to add MDMA (for PTSD), psilocybin (for depression), LSD, and other psychedelics to their offerings. Chuck Rifici, Canopy Growth co-founder, is on the company’s board of directors.

Numinus
(TSXV:NUMI,OTC Pink:LKYSF)

Numinus Bioscience is a healthcare company licensed through Health Canada to test, sell, and distribute psychedelic substances like Ketamine, Psilocybin, Psilocin, DMT, LSD, and Mescaline. They currently have a single facility in British Columbia, Canada, and plan to establish more locations throughout Canada soon.

Numinus Wellness
(OTCPK: LKYSF)

Numinus Wellness is a Canadian company that engages cultivation, research, development, and testing of both cannabis and certain psychedelics. Numinous also supports practitioners and facilitates guided psychedelic experiences, while developing treatment protocols for substances like ketamine, LSD, and psilocybin. These psychedelic stocks currently trade at less than $1.00 per share, though this is likely to increase substantially as the sector builds momentum.

Nutritional High International
(CSE:EAT,OTC Pink:SPLIF)

Nutritional High International renamed High Fusion in Sepember 2021, recently purchased the psychedelic business Psychedelic Science, thus earning the cannabis company’s way into the psychedelic space. The company researches psychedelic cacti for treating pain, anxiety, insomnia, and obesity. They are currently developing their products for FDA approval, after which they will file patents to protect their future market share.

Optimi Health
(CSE:OPTI,OTCQB:OPTHF)

Optimi Health develops functional mushroom-based formulas to promote positive emotional development. They operate two facilities in British Columbia where they cultivate and process therapeutic mushrooms. Notably, the company will soon launch commercial operations as they work to establish global leadership in the industry. They are currently seeking exemption through Health Canada to advance their psychedelic research.

Pharmadrug
(CSE:PHR)

Pharmadrug is an international drug company based out of Germany under the ownership of cannabis distributor Pharmadrug GmbH. However, they did not enter the psychedelic space until they acquired Super Smart, a Netherlands company that promotes the legal availability of psilocybin mushrooms in the country.

PharmaTher Holdings
(CSE:PHRM,OTCQB:PHRRF)

PharmaTher Holdings is a psychedelic biotech company focusing on ketamine therapy for depression, Parkinson’s Disease, and general pain. They are working to approve psychedelics for FDA approval, having already secured ketamine and esketamine, and are currently developing a patented microneedle patch for safer, more efficient psychedelic delivery.

PsyBio Therapeutics
(TSXV:PSYB,OTCQB:PSYBF)

PysBio Therapeutics develops therapeutic formulas from plants and fungi to help treat numerous mental health conditions. Notably, these biosynthetic psychoactive compounds promote mental health by helping the brain rewire trauma responses. Working with Miami University, PsyBio Therapeutics has developed proprietary technology to synthesize psilocybin and other active plant compounds for breakthrough mental health treatment.

Psyched Wellness
(CSE:PSYC,OTCQB:PSYCF)

Psyched Wellness is a Canadian health and wellness company that develops artisanal, medicinal mushroom supplements. Importantly, they have a strong focus on both environmental and societal sustainability with their organically farmed and Fair Trade products. They proudly boast their pure distilled psilocybin mushroom products for treating things like anxiety, stress, pain, and insomnia.

Psyence Group
(CSE:PSYG)

Psyence Group is a biotech company that researches and develops psilocybin-based medicines to help treat stress, depression, anxiety, PTSD, grief, and bereavement. They develop their products specifically for clinics and research institutions within multiple global jurisdictions. They also operate one of the forest federally approved psilocybin cultivation facilities in Southern Africa.

Red Light Holland
(CSE:TRIP)

Red Light Holland is a psychedelics company that produces and distributes “magic” truffles in the Netherlands. Notably, these are recreational psychedelics. However, the company plans to upgrade to medical-grade truffles pending certification through the European Union.

Revive Therapeutics
(CSE:RVV,OTCQB:RVVTF)

Revive Therapeutics is a cannabinoid pharmaceutical company that focuses on rare inflammatory issues. The company joined the psychedelics space when it purchased Psilocin Pharma, which already produces unique psilocybin formulas. Moving forward, Revive Therapeutics will continue to study psilocybin’s effect on various diseases and disorders. They are also exploring the benefit of Bucillamine against infectious diseases like COVID-19.

Roadman Investments
(TSXV:LITT)

Roadman Investments joined Psychedelic Insights to create a line of psychedelic clinics as a pharmaceutical-free alternative to mental healthcare. No doubt, this is just another one of many publicly traded psychedelic companies to watch soar.

Seelos Therapeutics
(NASDAQ:SEEL)

Seelos Therapeutics is a bio-pharmaceutical company that develops therapeutics to help treat Central Nervous System Disorders like ALS, Parkinson’s Disease, and more. The company received fast-track designation in 2019 for its ketamine therapy for those experiencing suicidal ideation and major depressive disorder.

Silo Wellness
(CSE:SILO,OTCQB:SILO)

Silo Wellness is a wellness company that focuses on psychedelics and functional mushrooms. They were also the first to announce a patent-pending psilocybin nasal, which the company hopes will address the most common issues consumers experience. Particularly, the nasal spray offers a better flavor, accurate dosing, and minimal nausea. Additionally, Silo Wellness offers guided psychedelic wellness retreats to help people release trauma and reach their higher selves. The Jamaican retreats last for about a week and involve yoga, meditation, and guided psychedelic experiences.

Tryp Therapeutics
(CSE:TRYP,OTQQB:TRYPF)

Tryp Therapeutics investigates the effectiveness of certain psychedelic compounds for treating rare conditions like fibromyalgia. They are currently Phase 2 ready for the expedited development of psilocybin-based pharmaceuticals for those with treatment-resistant health conditions.

Wesana Health Holdings
(Wesana Health Holdings (CSE:WESA,OTCQB:WSNAF))

Wesana Health Holdings develops psilocybin-based therapeutics to help treat neurological, psychological, and mental health problems. Additionally, the company also acquired Psychedelitech (PsyTech) through which they will promote their SaaS program Tovana Solutions. Notably, PsyTech Connect is the industry’s largest network of professional psychedelic practitioners.